entertainment -WSS

entertainment

author：knowledge 2025-10-01 00:49:15 - browse：316

Palm Drive at Stanford University on March 28, 2023 — Palm Drive at the entrance to Stanford University. Brian Frank for STAT

The resignation of Marc Tessier-Lavigne as president of Stanford University following an investigation into irregularities in his past research marks more than just the startling downfall of the leader of one of the nation’s top research powerhouses. The case is likely to have broader repercussions, signaling a tipping point in an ongoing and often contentious debate about how to assign blame and credit in the increasingly collaborative world of research.

Science is a team sport. And while the lab leaders, or principal investigators, often get most of the attention for biomedical breakthroughs, they seldom run experiments. That work is left to postdoctoral researchers, graduate students, and others who peer through microscopes, labor away in mouse rooms, and spend countless hours pipetting. Instead, professors play more of a managerial role, supervising, critiquing, and offering big-picture feedback on the work that goes on in their lab.

It’s a longstanding arrangement, but one that leads to a thorny question when research is challenged: Who’s to blame? STAT put that question to Stanford faculty and students while reporting earlier this year on allegations of image manipulation and other misconduct related to research in Tessier-Lavigne’s lab, as well as researchers at other institutions. The answer varied depending on whom you asked.

Graduate students stressed that since faculty have no qualms using work done in their labs to land grants, win prizes, and build prestige, they should ultimately be accountable for problems with the science done under their supervision. Faculty generally agree, at least in principle, but are often quick to say that there are limits to how closely they can scrutinize their lab’s work, and that team science is in part based on trust. It’s an argument Tessier-Lavigne cited in his own statement about his resignation.

It’s also one he said wasn’t good enough.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Insmed lung disease drug hits target in key Phase 3 trial

explore

WSS

Petition to FDA: Get the lead out of consumer hair dyes

First Opinion Podcast: What happens when kids become caregivers?

Addiction doctors spar with methadone clinics over legislation

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Lecanemab for Alzheimer's is coming. Is the health system ready?

Akili, maker of video game for ADHD, to be acquired for 34 million

Wikipedia

entertainment

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Iowa House, Senate pass 6

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Do more moles mean more problems? Not so, says new study

23andMe had bad news about my health. I wish a person had delivered it

Adam's Biotech Scorecard: Do Sarepta's exon

Psychedelics group wrestles with new pharma identity

A new study sees potential in DNA sequencing of infants

Tori Bowie and the unacceptable rates of Black maternal death

Addiction doctors spar with methadone clinics over legislation

hotspot

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Dark money group runs ads on China biotech bill

Palantir health business leans on meeting customers’ needs

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

What to know about OceanGate, the company behind the missing Titanic submersible

Startling documents reveal new facets of Sacklers' opioid empire

explore

knowledge

explore

hotspot